This small biotech could grow much larger with some good news from its pipeline.

Iovance Biotherapeutics argues that there is a meaningful opportunity here of more than 8,000 patients diagnosed annually in ...

Revolution Medicines announces positive Phase 3 clinical trial results for its pancreatic cancer treatment.

While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to continue.

Vir Biotechnology (VIR) has advanced its oncology program by dosing the first patient in a Phase 1 expansion cohort for VIR-5500 in metastatic prostate cancer, following encouraging early safety and ...

Since then, the stock has delivered market-beating returns thanks to significant clinical and regulatory progress, as well as ...

Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, ...

Revolution Medicines (RVMD) is one of the best stocks on Wall Street today after breakthrough cancer pill results ...

Now, it’s worth noting Stock Advisor’s total average return is 930 % — a market-crushing outperformance compared to 185% for ...

This oncology-focused biotech, advancing multiple clinical-stage therapeutics, just reported a notable insider sale in recent ...

Learning how to trade biotech stocks offers some of the most explosive profit opportunities in the entire market—but also some of its most punishing risks. Biotech stocks can double or triple ...

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes — the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) — ...